Skip to main content
Premium Trial:

Request an Annual Quote

The BioCommerce Week Index: Mar 31, 2005

BioCommerce Week’s Index to the
Diversified Molecular Biology Tools Companies
Company
Ticker
Current Price
(March 29, 2005)
Last Price
(
March 22, 2005)
% Change
Agilent
A
22.48
22.58
-0.44
Applied Biosystems
ABI
20.32
20.36
-0.20
BD
BDX
58.90
58.62
0.48
Beckman
BEC
67.89
68.90
-1.47
Bio-Rad
BIO
48.41
48.00
0.85
Bruker
BRKR
3.46
3.26
6.13
GE
GE
35.53
35.50
0.08
Harvard Bio
HBIO
3.86
4.08
-5.39
Invitrogen
IVGN
71.10
71.31
-0.29
Molecular Devices
MDCC
19.71
18.98
3.85
PerkinElmer
PKI
21.15
21.00
0.71
Sigma
SIAL
62.30
62.07
0.37
Stratagene
STGN
8.00
8.05
-0.62
Thermo
TMO
25.26
25.33
-0.28
Waters
WAT
46.26
46.67
-0.88
Index Average
34.31
34.31
-0.02

 

Bruker Shares Gain 6 Percent After
Last Week's 17-Percent Tumble

Bruker shares gained 6 percent and Molecular Devices gained 4 percent on the weekly period tracked in the BioCommerce Week Index ending Tuesday.

The companies were the only members of the 15 firms followed in the index to post significant gains on the holiday-shortened period. Harvard Bio lost 5 percent to lead eight companies whose shares fell in the period.

Bruker's gains followed a 17-percent loss in its market capitalization last week after the company announced that it would request an extension of the deadline for filing its 10-K report. The company said it would restate its net loss between $0.07 and $0.09 a share from its previously reported $0.06 a share after finding a "material weakness" in its internal controls at one of its subsidiaries. Bruker shares have finished up in four out of the last five weeks.

Waters, which slashed its first-quarter revenue growth expectations to 3 percent to 4 percent from its previous outlook of 13 percent, after market close Tuesday, was down just under 1 percent for the week . In the first 40 minutes of trading Wednesday, Waters shares fell 22 percent, representing one fifth of the firm's market capitalization, or $1.2 billion. (See article).

Overall, the index fell 0.02 percent for the week, closing at $34.31 with its third consecutive week of losses. The index, which was launched Sept. 9, reached a high of $36.10 on Feb. 8, but has fallen in five out of the seven weeks since then.

Still, the index outperformed the Dow, which finished down 1.6 percent for the week; the S&P 500, which was down 1.7; and the Nasdaq, which was off 1.8 percent. The Amex biotech index was down 1.9 percent for the week while the Amex pharma index finished up a fraction of a percent.

 

The Scan

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.

Study Offers Insights Into Role of Structural Variants in Cancer

A new study in Nature using cell lines shows that structural variants can enable oncogene activation.

Computer Model Uses Genetics, Health Data to Predict Mental Disorders

A new model in JAMA Psychiatry finds combining genetic and health record data can predict a mental disorder diagnosis before one is made clinically.

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.